{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:40Z","timestamp":1792896940671,"version":"4.5.0"},"reference-count":91,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Viral infections are common and are potentially life-threatening in patients with moderate to severe primary immunodeficiency disorders. Because T-cell immunity contributes to the control of many viral pathogens, adoptive immunotherapy with virus-specific T cells (VSTs) has been a logical and effective way of combating severe viral disease in immunocompromised patients in multiple phase 1 and 2 clinical trials. Common viral targets include cytomegalovirus, Epstein-Barr virus, and adenovirus, though recent published studies have successfully targeted additional pathogens, including HHV6, BK virus, and JC virus. Though most studies have used VSTs derived from allogenic stem cell donors, the use of banked VSTs derived from partially HLA-matched donors has shown efficacy in multicenter settings. Hence, this approach could shorten the time for patients to receive VST therapy thus improving accessibility. In this review, we discuss the usage of VSTs for patients with primary immunodeficiency disorders in clinical trials, as well as future potential targets and methods to broaden the applicability of virus-directed T-cell immunotherapy for this vulnerable patient population.<\/jats:p>","DOI":"10.1182\/blood.2019000924","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T01:09:35Z","timestamp":1579136975000},"page":"620-628","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["Virus-specific T-cell therapies for patients with primary immune deficiency"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-3085","authenticated-orcid":false,"given":"Michael D.","family":"Keller","sequence":"first","affiliation":[{"name":"Center for Cancer and Immunology Research and"},{"name":"Division of Allergy and Immunology, Children\u2019s National Health System, Washington, DC;"},{"name":"GW Cancer Center, George Washington University, Washington, DC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-9090","authenticated-orcid":false,"given":"Catherine M.","family":"Bollard","sequence":"first","affiliation":[{"name":"Center for Cancer and Immunology Research and"},{"name":"GW Cancer Center, George Washington University, Washington, DC; and"},{"name":"Division of Blood and Marrow Transplantation, Children\u2019s National Health System, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2020022706595011400_B1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2020022706595011400_B2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10875-017-0465-8","article-title":"The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies","volume":"38","author":"Bousfiha","year":"2018","journal-title":"J Clin Immunol"},{"issue":"5","key":"2020022706595011400_B3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2020022706595011400_B4","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020022706595011400_B5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2300","article-title":"Newborn screening for severe combined immunodeficiency and t-cell lymphopenia in California, 2010-2017","volume":"143","author":"Amatuni","year":"2019","journal-title":"Pediatrics"},{"issue":"7","key":"2020022706595011400_B6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States [published correction appears in JAMA. 2014;312:2169]","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"2020022706595011400_B7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood-2017-09-807487","article-title":"Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency","volume":"131","author":"Fox","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2020022706595011400_B8","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020022706595011400_B9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2020022706595011400_B10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/10428190601059837","article-title":"EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning","volume":"48","author":"Cohen","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2020022706595011400_B11","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020022706595011400_B12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2020022706595011400_B13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"25","key":"2020022706595011400_B42","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"2020022706595011400_B14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"2020022706595011400_B15","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"issue":"10","key":"2020022706595011400_B16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2020022706595011400_B17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/14653249.2012.663486","article-title":"Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients","volume":"14","author":"Blyth","year":"2012","journal-title":"Cytotherapy"},{"issue":"11","key":"2020022706595011400_B18","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"242","key":"2020022706595011400_B19","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"2020022706595011400_B20","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","article-title":"Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2020022706595011400_B21","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2020022706595011400_B22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2020022706595011400_B23","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"issue":"9","key":"2020022706595011400_B24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u201coff the shelf\u201d adoptive therapy of refractory infections","volume":"51","author":"O\u2019Reilly","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"2020022706595011400_B25","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2020022706595011400_B26","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"24","key":"2020022706595011400_B27","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"issue":"31","key":"2020022706595011400_B28","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020022706595011400_B29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CJI.0b013e31824300a2","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J Immunother"},{"key":"2020022706595011400_B30","first-page":"920","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume-title":"J Allergy Clin Immunol","author":"Creidy","year":"2016"},{"issue":"6","key":"2020022706595011400_B31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/jix358","article-title":"Immunologic profiling of human metapneumovirus for the development of targeted immunotherapy","volume":"216","author":"Tzannou","year":"2017","journal-title":"J Infect Dis"},{"key":"2020022706595011400_B32","first-page":"1498","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume-title":"J Allergy Clin Immunol","author":"Naik","year":"2016"},{"issue":"11","key":"2020022706595011400_B33","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"issue":"19","key":"2020022706595011400_B34","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2020022706595011400_B35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2020022706595011400_B36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1470-2045(05)70171-6","article-title":"Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation","volume":"6","author":"Wynn","year":"2005","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020022706595011400_B37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2020022706595011400_B38","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.bbmt.2018.04.030","article-title":"Antiviral T cells for adenovirus in the pretransplant period: a bridge therapy for severe combined immunodeficiency","volume":"24","author":"Miller","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020022706595011400_B39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10875-014-0125-1","article-title":"Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation","volume":"35","author":"Punwani","year":"2015","journal-title":"J Clin Immunol"},{"issue":"14","key":"2020022706595011400_B40","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients [published correction appears in Blood Adv. 2019;3(16):2453]","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2020022706595011400_B89","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"2020022706595011400_B90","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"2020022706595011400_B45","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/bloodadvances.2019000371","article-title":"\u201cMini\u201d bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2020022706595011400_B41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"2020022706595011400_B43","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2020022706595011400_B44","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00268-17","article-title":"Progress toward development of a vaccine against congenital cytomegalovirus infection","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"Pt 1","key":"2020022706595011400_B46","first-page":"241","article-title":"Primary immunodeficiencies associated with EBV disease","volume":"390","author":"Cohen","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"issue":"22","key":"2020022706595011400_B47","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"30","key":"2020022706595011400_B48","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020022706595011400_B49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2020022706595011400_B50","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020022706595011400_B51","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/08880018.2012.714844","article-title":"Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen","volume":"29","author":"Boztug","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"2020022706595011400_B52","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.bmt.1702656","article-title":"Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit","volume":"26","author":"Crooks","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2020022706595011400_B53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CJI.0b013e31815ef862","article-title":"Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation","volume":"31","author":"Feuchtinger","year":"2008","journal-title":"J Immunother"},{"issue":"1","key":"2020022706595011400_B54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12208","article-title":"Progressive multifocal leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic cell transplantation (HCT)","volume":"92","author":"Kaufman","year":"2014","journal-title":"Eur J Haematol"},{"issue":"4","key":"2020022706595011400_B55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbmt.2015.12.009","article-title":"Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Philippe","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020022706595011400_B56","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/bmt.2017.175","article-title":"Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Ogata","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2020022706595011400_B57","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199811263392201","article-title":"Outcomes among 562 recipients of placental-blood transplants from unrelated donors","volume":"339","author":"Rubinstein","year":"1998","journal-title":"N Engl J Med"},{"issue":"285","key":"2020022706595011400_B58","doi-asserted-by":"crossref","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med"},{"key":"2020022706595011400_B59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtm.2017.02.001","article-title":"Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood","volume":"5","author":"Dave","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"18","key":"2020022706595011400_B60","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2020022706595011400_B61","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.16053","article-title":"T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy","volume":"187","author":"Keller","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"2020022706595011400_B62","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2020022706595011400_B63","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020022706595011400_B64","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2020022706595011400_B65","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"39","key":"2020022706595011400_B66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16","key":"2020022706595011400_B67","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2020022706595011400_B68","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hon.2481","article-title":"Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"36","author":"Ureshino","year":"2018","journal-title":"Hematol Oncol"},{"issue":"12","key":"2020022706595011400_B69","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.bbmt.2018.10.010","article-title":"Build a bank: off-the-shelf virus-specific T cells","volume":"24","author":"Hanley","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020022706595011400_B70","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0198-8859(03)00028-4","article-title":"Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles","volume":"64","author":"Lacey","year":"2003","journal-title":"Hum Immunol"},{"issue":"8","key":"2020022706595011400_B71","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/00007890-200110270-00012","article-title":"Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells","volume":"72","author":"Haque","year":"2001","journal-title":"Transplantation"},{"issue":"12","key":"2020022706595011400_B72","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.4049\/jimmunol.160.12.6204","article-title":"Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients","volume":"160","author":"Haque","year":"1998","journal-title":"J Immunol"},{"issue":"6","key":"2020022706595011400_B73","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MPH.0b013e31819daf60","article-title":"Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease","volume":"31","author":"Rao","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2020022706595011400_B74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/cei.12966","article-title":"The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis","volume":"189","author":"Schinnerling","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2020022706595011400_B75","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2020022706595011400_B76","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2020022706595011400_B77","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2020022706595011400_B78","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"issue":"12","key":"2020022706595011400_B79","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jcyt.2016.08.010","article-title":"Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes","volume":"18","author":"McLaughlin","year":"2016","journal-title":"Cytotherapy"},{"issue":"1","key":"2020022706595011400_B80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcyt.2016.09.013","article-title":"Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy","volume":"19","author":"Ma","year":"2017","journal-title":"Cytotherapy"},{"issue":"3","key":"2020022706595011400_B81","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jcyt.2017.11.010","article-title":"Human papilloma virus-specific T cells can be generated from na\u00efve T cells for use as an immunotherapeutic strategy for immunocompromised patients","volume":"20","author":"McCormack","year":"2018","journal-title":"Cytotherapy"},{"issue":"3","key":"2020022706595011400_B82","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcyt.2012.11.014","article-title":"Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes","volume":"15","author":"Tramsen","year":"2013","journal-title":"Cytotherapy"},{"key":"2020022706595011400_B83","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fimmu.2019.00621","article-title":"Mycobacteria-specific T cells may be expanded from healthy donors and are near absent in primary immunodeficiency disorders","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"2020022706595011400_B84","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.omtm.2018.03.003","article-title":"A new method for reactivating and expanding T cells specific for Rhizopus oryzae","volume":"9","author":"Castillo","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2020022706595011400_B91","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2018.206896","article-title":"Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections","volume":"105","author":"Vasileiou","year":"2020","journal-title":"Haematologica"},{"issue":"23","key":"2020022706595011400_B85","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood-2009-07-228387","article-title":"Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease","volume":"114","author":"Brewin","year":"2009","journal-title":"Blood"},{"issue":"26","key":"2020022706595011400_B86","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2015-08-664755","article-title":"TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells","volume":"126","author":"Menger","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2020022706595011400_B87","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"2020022706595011400_B88","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of progressive multifocal leukoencephalopathy with pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/9\/620\/1717458\/bloodbld2019000924c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/9\/620\/1717458\/bloodbld2019000924c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:01:04Z","timestamp":1695618064000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/9\/620\/431025\/Virusspecific-Tcell-therapies-for-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000924","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}